Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: A double‐blind, randomized trial

Marsha Y. Morgan, Katherine E. Hawley – 1 November 1987 – Lactitol (β‐galactosido‐sorbitol) is a nonabsorbable disaccharide available as a powder which, in open comparison, is as effective as lactulose in the treatment of chronic hepatic encephalopathy, but is better tolerated. Twenty‐five cirrhotic patients experiencing 28 episodes of acute hepatic encephalopathy were randomized blindly to treatment with either lactitol (n = 15) or lactulose (n = 13).

Acute non‐B hepatitis in the Israel defence forces: Comparison of some epidemiologic features before and after the usage of preexposure immune serum globulin prophylaxis

Haim Matzkin – 1 November 1987 – Large‐scale epidemics of non‐B (HBsAg‐negative) hepatitis have occurred in the Israel Defense Forces prior to post‐ and preexposure immune serum globulin administration. Presently, hepatitis morbidity rates have stabilized around 1 to 2 per 1,000. Several years after vaccine initiation, a comparison of epidemiological features was made in order to redefine risk groups.

Portal‐systemic shunts for Budd‐Chiari syndrome

Marshall J. Orloff – 1 November 1987 – Nine patients with Budd‐Chiari syndrome (BCS) were treated by a portal systemic shunt. One had thrombosis of the superior mesenteric vein (SMV) and another had complete obstruction of the retrohepatic inferior vena cava (IVC). All other patients had a marked stenosis of the retrohepatic IVC with caval pressure ranging from 12 to 24 mmHg (mean: 17 mmHg). Seven patients had an interprosition mesocaval shunt using an autologous jugular vein. The patient with a thrombosed SMV had a portoartial shunt.

Interleukin 1: Regulation of hepatic carbohydrate metabolism by insulin or insulinomimesis

Oliver E. Owen – 1 November 1987 – The purpose of this study was to investigate the effect of interleukin 1 (IL 1) on glucocorticoid‐regulated hepatic metabolism. Steroid binding in liver cytosol, plasma glucose, plasma corticoster‐one, and phosphenolpyruvate carboxykinase (PEPCK) activity were assayed in C3H/HeJ mice after IL 1 administration. Mice received 5 pyrogenic U (PU) of rabbit IL 1 i.p. and were sacrificed 4 hr later.

Inhibition of human cationic glutathione S‐transferase by nonsubstrate ligands

Thomas D. Boyer, Donald A. Vessey – 1 September 1987 – Inhibition of a major hepatic form of human cationic glutathione S‐transferase by bilirubin, biliverdin, indocyanine green and chenodeoxycholic acid was investigated as a function of pH (range = 6.5 to 9.1). Changes in pH had little effect on the extent of inhibition by indocyanine green. However, inhibition by bilirubin, biliverdin and chenodeoxycholic acid was found to be pH‐dependent, with markedly less inhibition at the high values of pH.

Procollagen III peptide (PIIIP): Can it reflect hepatic fibrosis?

Joseph Alcorn, Mario Chojkier – 1 September 1987 – Immunolocalization of type III collagen and procollagen in cirrhotic human liver was studied using monoclonal antibody specific for the helical determinant of type III collagen extracted from human placenta. Deparaffinized, trypsin‐treated cirrhotic liver sections from 8 autopsy cases were examined by the unlabeled peroxidase‐antiperoxidase and immunofluorescence techniques.

Hepatic disease in patients with the acquired immune deficiency syndrome (AIDS)

David J. Schneiderman, David M. Arenson, John P. Cello, William Margaretten, Thomas E. Weber – 1 September 1987 – The spectrum of liver disease in patients with acquired immune deficiency syndrome (AIDS) and the clinical impact of diagnostic percutaneous liver biopsy in this population were evaluated by a retrospective review of hepatic histology, clinical features and laboratory data in 85 patients (26 biopsies, 59 autopsies). Only 1 (3.8%) biopsy and 9 (15%) postmortem livers were histologically normal.

Subscribe to